US Patent Issued to Alnylam Pharmaceuticals on Feb. 17 for "Transmembrane serine protease 2 (TMPRSS2) iRNA compositions and methods of use thereof" (Massachusetts Inventors)

ALEXANDRIA, Va., Feb. 17 -- United States Patent no. 12,553,053, issued on Feb. 17, was assigned to Alnylam Pharmaceuticals Inc. (Cambridge, Mass.).

"Transmembrane serine protease 2 (TMPRSS2) iRNA compositions and methods of use thereof" was invented by Akin Akinc (Needham, Mass.), James D. McIninch (Burlington, Mass.), Yesseinia Anglero-Rodriguez (Cambridge, Mass.) and Mark K. Schlegel (Boston).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the transmembrane serine protein 2 (TMPRSS2) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a TMPRSS2 gene and to methods of treating or preventing ...